Advanz Pharma’s business development team is busty assessing potential deals as the recapitalized company works towards restoring profitability on an eroding revenues base.

Pfenex remains hopeful of receiving US approval for its teriparatide hybrid rival to Eli Lilly’s Forteo in October this year. But commercial partner Alvogen may have to wait for a therapeutic equivalence rating to the osteoporosis original.

By acquiring global rights to epinephrine and naloxone nasal spray candidates from Insys, Hikma is following its strategy of moving its non-injectable Generics business segment in the US towards differentiated products.

Endo has high hope for its pipeline of 505(b)(2) hospital and critical-care drugs in the US as the group looks to return to revenue growth.

Hybrid 505(b)(2) rivals to Lilly’s Alimta from Dr Reddy’s and Pfizer do not literally infringe a key method-of-treatment patent protecting the pemetrexed brand until May 2022. But their alternative salts infringe under the doctrine of equivalents, the US Court of Appeals has confirmed.

Firms now have until 23 August to enter the Global Generics & Biosimilars Awards 2019.